In the present manuscript it was presented whether spreading of antibiotic resistant bacterial groups in environment could be monitored by our newly developed method by enumerating antibiotic resistant bacterial group...In the present manuscript it was presented whether spreading of antibiotic resistant bacterial groups in environment could be monitored by our newly developed method by enumerating antibiotic resistant bacterial groups in various biological wastes and composts. Although the numbers were not so high, diverse kinds of colistin resistant bacteria (25 mg·L<sup>-1</sup><sup></sup>) were included in row cattle feces (1.78 × 10<sup>4</sup> MPN g<sup>-1</sup>) and cattle feces manure (>3.84 × 10<sup>4</sup> MPN g<sup>-1</sup>). Compost originated from leftover food (>44.8 × 10<sup>4</sup> MPN g<sup>-1</sup>) and shochu lee (>320 × 10<sup>4</sup> MPN g<sup>-1</sup>) included higher numbers of chlortetracycline resistant Pseudomonas sp., (25 mg·L<sup>-1</sup><sup></sup>), and row cattle feces included higher numbers of chlortetracycline resistant Enterobacteriacea (15.7 × 10<sup>4</sup> MPN g<sup>-1</sup>), which mostly consisted from Pantoea sp. or Xenorhobdus doucetiae. Numbers of multi drug resistant bacteria, resistant to 25 mg·L<sup>-1 </sup>of<sup> </sup>ciprofloxacin, streptomycin, chloramphenicol, and ampicillin, were the highest in row cattle feces (>143.6 × 10<sup>4</sup> MPN g<sup>-1</sup>), followed by cattle feces manure (4.19 × 10<sup>4</sup> MPN g<sup>-1</sup>), and shochu lee (0.36 × 10<sup>4</sup> MPN g<sup>-1</sup>), which included diverse kinds of bacterial group. The present results indicated that higher numbers of multi drug resistant bacteria were typically found in row cattle feces, and the method was found suitable to enumerate and identify them. These results suggested that the method might become their environmental risk evaluation method.展开更多
OBJECTIVE:To evaluate the efficacy and safety of Buzhong Yiqi decoction(补中益气汤,BZYQ)in the treatment of hospital-acquired pneumonia(HAP)with multi-drug-resistant bacteria(MDRB).METHODS:This 28-day study was conduc...OBJECTIVE:To evaluate the efficacy and safety of Buzhong Yiqi decoction(补中益气汤,BZYQ)in the treatment of hospital-acquired pneumonia(HAP)with multi-drug-resistant bacteria(MDRB).METHODS:This 28-day study was conducted at 5 clinical centers in Shanghai.The eligible patients were randomly assigned(1∶1)into the intervention group(BZYQ plus conventional Western Medicine therapy)and control group(conventional Western Medicine therapy).The primary outcomes were the clinical response,clinical pulmonary infection score(CPIS),and microbiologic response.The secondary outcomes were the 28-day allcause mortality(ACM),Acute Physiology and Chronic Health EvaluationⅡ(APACHEⅡ)score,ventilator weaning rate,length of mechanical ventilation(MV),length of hospital stay,and changes of infection indicators.RESULTS:Altogether 83 subjects in the intervention group and 85 subjects in the control group were analyzed.The clinical success rate(48.2%)and the pathogen eradication rate(59.0%)of the intervention group were all better than those of the control group(32.9%and 38.9%,respectively)with statistically significant differences(P<0.05).The CPIS score of the intervention group(8.9±1.7)was lower than that of the control group(9.6±2.5)(P<0.05).The length of MV in the intervention group[(13.7±6.4)d]was significantly shorter than that of the control group[(17.2±7.2)d](P<0.05).The 28-day ACM of the intervention group(13.33%)was lower than that of the control group(21.2%)with no statistically significant difference(P>0.05).The differences between two groups in ventilator weaning rate,length of hospital stay,and APACHEⅡscore were not statistically significant(P>0.05).The intervention group displayed decreases in white blood cell count,C-reactive protein,neutrophil percentage,and procalcitonin at day 28 compared with baseline(P<0.05).No serious adverse events occurred in either group during the 28-day follow-up.CONCLUSION:BZYQ may be an effective therapeutic option for the management of HAP with MDRB.展开更多
目的探讨急诊重症监护室(emergency intensive care unit,EICU)血流感染患者临床结局的风险因子,为临床决策提供依据。方法回顾性收集2019年1月至2023年4月我院就诊的141例EICU血流感染患者的病历资料及血培养记录,采用Logistic回归分...目的探讨急诊重症监护室(emergency intensive care unit,EICU)血流感染患者临床结局的风险因子,为临床决策提供依据。方法回顾性收集2019年1月至2023年4月我院就诊的141例EICU血流感染患者的病历资料及血培养记录,采用Logistic回归分析患者死亡的危险因素,运用Cox回归分析上述因素与患者生存时间和临床结局的关系。结果在141例EICU血流感染患者中,两种及以上细菌混合血流感染[比值比(OR)=5.68,95%置信区间(CI):1.20~26.98,P<0.05]及多重耐药菌血流感染(OR=6.39,95%CI:2.78~14.67,P<0.01)与患者死亡具有显著相关性;是否根据药敏结果及时调整用药[风险比(HR)=0.47,95%CI:0.30~0.74]和多重耐药菌血流感染(HR=2.02,95%CI:1.28~3.20)是EICU血流感染患者死亡的风险因子(P<0.01)。结论尽早采集血培养,明确感染病原菌,精准用药控制感染,可以有效降低患者的死亡率。展开更多
目的·分析中度重症急性胰腺炎(moderately severe acute pancreatitis,MSAP)和重症急性胰腺炎(severe acute pancreatitis,SAP)继发胰腺/胰周革兰阴性耐药菌感染的来源、菌种特点及其对病程和预后的影响。方法·回顾2013—201...目的·分析中度重症急性胰腺炎(moderately severe acute pancreatitis,MSAP)和重症急性胰腺炎(severe acute pancreatitis,SAP)继发胰腺/胰周革兰阴性耐药菌感染的来源、菌种特点及其对病程和预后的影响。方法·回顾2013—2017年上海交通大学医学院附属瑞金医院急诊科、胰腺外科与重症医学科收治的符合研究条件的患者,筛选胰腺/胰周革兰阴性菌(Gram-negative bacteria,GNB)感染的患者,并分为多重耐药(multiple drug resistant,MDR)革兰阴性菌(MDR-GNB)组和非多重耐药革兰阴性菌(non-MDRGNB)组,对比分析基础临床信息、耐药菌的来源、耐药菌感染对病情进展及预后的影响。结果·共收治197例MSAP和SAP患者,胰腺/胰周标本明确GNB感染92例(46.70%),其中MDR-GNB感染患者61例(占66.30%),non-MDR-GNB感染患者31例(占33.70%);胰腺/胰周标本共检出117株GNB,其中MDR-GNB 69株,主要是多重耐药肺炎克雷伯杆菌(Klebsiella pneumoniae,KP)(MDR-KP)(39株,56.52%)和多重耐药鲍曼不动杆菌(Acinetobacter baumannii,AB)(MDR-AB)(22株,31.88%);MDR-GNB组经皮穿刺置管引流(percutaneous catheter drainage,PCD)继发耐药菌感染的发生率显著高于non-MDR-GNB组(36.07%vs 12.90%,P=0.020);耐药菌感染可导致机械通气时间延长[(17.65±11.74) d vs (9.67±9.34) d,P=0.001]、碳青霉烯类和特殊抗菌药物使用增加(P=0.000)、首次开腹手术时间提前[(21.92±11.45) d vs (29.36±21.48) d,P=0.032]、≥2次开腹手术发生率增高(45.90%vs 22.58%,P=0.029)、总住院时间延长(54.44±42.38) d vs (32.51±27.62) d,P=0.011)和病死率增高(34.43%vs 12.90%,P=0.028);死亡患者中MDR-KP的感染率显著高于存活患者(85.71%vs 52.50%,P=0.000),而其他耐药菌在2组中差异均无统计学意义。结论·MSAP和SAP继发胰腺/胰周革兰阴性耐药菌感染的患者中,MDR-KP和MDR-AB占据了主导地位。耐药菌感染的来源中,PCD继发感染的发生率最高。耐药菌感染可导致病程延长、用药和手术增加及预后不良,其中MDR-KP的感染更是与预后不良直接相关。展开更多
文摘In the present manuscript it was presented whether spreading of antibiotic resistant bacterial groups in environment could be monitored by our newly developed method by enumerating antibiotic resistant bacterial groups in various biological wastes and composts. Although the numbers were not so high, diverse kinds of colistin resistant bacteria (25 mg·L<sup>-1</sup><sup></sup>) were included in row cattle feces (1.78 × 10<sup>4</sup> MPN g<sup>-1</sup>) and cattle feces manure (>3.84 × 10<sup>4</sup> MPN g<sup>-1</sup>). Compost originated from leftover food (>44.8 × 10<sup>4</sup> MPN g<sup>-1</sup>) and shochu lee (>320 × 10<sup>4</sup> MPN g<sup>-1</sup>) included higher numbers of chlortetracycline resistant Pseudomonas sp., (25 mg·L<sup>-1</sup><sup></sup>), and row cattle feces included higher numbers of chlortetracycline resistant Enterobacteriacea (15.7 × 10<sup>4</sup> MPN g<sup>-1</sup>), which mostly consisted from Pantoea sp. or Xenorhobdus doucetiae. Numbers of multi drug resistant bacteria, resistant to 25 mg·L<sup>-1 </sup>of<sup> </sup>ciprofloxacin, streptomycin, chloramphenicol, and ampicillin, were the highest in row cattle feces (>143.6 × 10<sup>4</sup> MPN g<sup>-1</sup>), followed by cattle feces manure (4.19 × 10<sup>4</sup> MPN g<sup>-1</sup>), and shochu lee (0.36 × 10<sup>4</sup> MPN g<sup>-1</sup>), which included diverse kinds of bacterial group. The present results indicated that higher numbers of multi drug resistant bacteria were typically found in row cattle feces, and the method was found suitable to enumerate and identify them. These results suggested that the method might become their environmental risk evaluation method.
基金Basic Research Program of Shanghai Municipal Science and Technology Commission:A MulticenterRandomized+2 种基金Controlled Clinical Study on Fuzheng Quxie Jing Prescription"Buzhong Yiqi Decoction"in the Treatment of Hospital-acquired Pneumonia caused by Multi-drug Resistant Bacteria(No.18401971600)Three-year Action Plan for the Development of Traditional Chinese Medicine in Shanghai:National TCM Emergency Medical Rescue Base Construction[No.ZY(2021-2023)-0101-01]East China Area and Municipal TCM Specialty Disease Alliance Construction[No.ZY(2021-2023)-0302]。
文摘OBJECTIVE:To evaluate the efficacy and safety of Buzhong Yiqi decoction(补中益气汤,BZYQ)in the treatment of hospital-acquired pneumonia(HAP)with multi-drug-resistant bacteria(MDRB).METHODS:This 28-day study was conducted at 5 clinical centers in Shanghai.The eligible patients were randomly assigned(1∶1)into the intervention group(BZYQ plus conventional Western Medicine therapy)and control group(conventional Western Medicine therapy).The primary outcomes were the clinical response,clinical pulmonary infection score(CPIS),and microbiologic response.The secondary outcomes were the 28-day allcause mortality(ACM),Acute Physiology and Chronic Health EvaluationⅡ(APACHEⅡ)score,ventilator weaning rate,length of mechanical ventilation(MV),length of hospital stay,and changes of infection indicators.RESULTS:Altogether 83 subjects in the intervention group and 85 subjects in the control group were analyzed.The clinical success rate(48.2%)and the pathogen eradication rate(59.0%)of the intervention group were all better than those of the control group(32.9%and 38.9%,respectively)with statistically significant differences(P<0.05).The CPIS score of the intervention group(8.9±1.7)was lower than that of the control group(9.6±2.5)(P<0.05).The length of MV in the intervention group[(13.7±6.4)d]was significantly shorter than that of the control group[(17.2±7.2)d](P<0.05).The 28-day ACM of the intervention group(13.33%)was lower than that of the control group(21.2%)with no statistically significant difference(P>0.05).The differences between two groups in ventilator weaning rate,length of hospital stay,and APACHEⅡscore were not statistically significant(P>0.05).The intervention group displayed decreases in white blood cell count,C-reactive protein,neutrophil percentage,and procalcitonin at day 28 compared with baseline(P<0.05).No serious adverse events occurred in either group during the 28-day follow-up.CONCLUSION:BZYQ may be an effective therapeutic option for the management of HAP with MDRB.
文摘目的探讨急诊重症监护室(emergency intensive care unit,EICU)血流感染患者临床结局的风险因子,为临床决策提供依据。方法回顾性收集2019年1月至2023年4月我院就诊的141例EICU血流感染患者的病历资料及血培养记录,采用Logistic回归分析患者死亡的危险因素,运用Cox回归分析上述因素与患者生存时间和临床结局的关系。结果在141例EICU血流感染患者中,两种及以上细菌混合血流感染[比值比(OR)=5.68,95%置信区间(CI):1.20~26.98,P<0.05]及多重耐药菌血流感染(OR=6.39,95%CI:2.78~14.67,P<0.01)与患者死亡具有显著相关性;是否根据药敏结果及时调整用药[风险比(HR)=0.47,95%CI:0.30~0.74]和多重耐药菌血流感染(HR=2.02,95%CI:1.28~3.20)是EICU血流感染患者死亡的风险因子(P<0.01)。结论尽早采集血培养,明确感染病原菌,精准用药控制感染,可以有效降低患者的死亡率。
文摘目的·分析中度重症急性胰腺炎(moderately severe acute pancreatitis,MSAP)和重症急性胰腺炎(severe acute pancreatitis,SAP)继发胰腺/胰周革兰阴性耐药菌感染的来源、菌种特点及其对病程和预后的影响。方法·回顾2013—2017年上海交通大学医学院附属瑞金医院急诊科、胰腺外科与重症医学科收治的符合研究条件的患者,筛选胰腺/胰周革兰阴性菌(Gram-negative bacteria,GNB)感染的患者,并分为多重耐药(multiple drug resistant,MDR)革兰阴性菌(MDR-GNB)组和非多重耐药革兰阴性菌(non-MDRGNB)组,对比分析基础临床信息、耐药菌的来源、耐药菌感染对病情进展及预后的影响。结果·共收治197例MSAP和SAP患者,胰腺/胰周标本明确GNB感染92例(46.70%),其中MDR-GNB感染患者61例(占66.30%),non-MDR-GNB感染患者31例(占33.70%);胰腺/胰周标本共检出117株GNB,其中MDR-GNB 69株,主要是多重耐药肺炎克雷伯杆菌(Klebsiella pneumoniae,KP)(MDR-KP)(39株,56.52%)和多重耐药鲍曼不动杆菌(Acinetobacter baumannii,AB)(MDR-AB)(22株,31.88%);MDR-GNB组经皮穿刺置管引流(percutaneous catheter drainage,PCD)继发耐药菌感染的发生率显著高于non-MDR-GNB组(36.07%vs 12.90%,P=0.020);耐药菌感染可导致机械通气时间延长[(17.65±11.74) d vs (9.67±9.34) d,P=0.001]、碳青霉烯类和特殊抗菌药物使用增加(P=0.000)、首次开腹手术时间提前[(21.92±11.45) d vs (29.36±21.48) d,P=0.032]、≥2次开腹手术发生率增高(45.90%vs 22.58%,P=0.029)、总住院时间延长(54.44±42.38) d vs (32.51±27.62) d,P=0.011)和病死率增高(34.43%vs 12.90%,P=0.028);死亡患者中MDR-KP的感染率显著高于存活患者(85.71%vs 52.50%,P=0.000),而其他耐药菌在2组中差异均无统计学意义。结论·MSAP和SAP继发胰腺/胰周革兰阴性耐药菌感染的患者中,MDR-KP和MDR-AB占据了主导地位。耐药菌感染的来源中,PCD继发感染的发生率最高。耐药菌感染可导致病程延长、用药和手术增加及预后不良,其中MDR-KP的感染更是与预后不良直接相关。
